Pharmacological Treatment of Alcohol Cravings

Imagem de Miniatura
Arquivos
art_MARIN_Pharmacological_Treatment_of_Alcohol_Cravings_2023.PDF (746.25 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
PERROTTE, Giuliana
CASTALDELLI, Fernando Ikeda
SANTOS, Maria Beatriz Brisola dos
CAMPOS, Marcela Waisman
Citação
BRAIN SCIENCES, v.13, n.8, article ID 1206, 28p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
(1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.
Palavras-chave
craving, alcohol, randomi* controlled blind*
URI
https://observatorio.fm.usp.br/handle/OPI/56174
Referências
  1. Addolorato G, 2002, ALCOHOL ALCOHOLISM, V37, P504, DOI 10.1093/alcalc/37.5.504
  2. Agabio R, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008581.pub2
  3. Ait-Daoud N, 2001, PSYCHOPHARMACOLOGY, V154, P23, DOI 10.1007/s002130000607
  4. Alho H, 2002, ALCOHOL CLIN EXP RES, V26, P1816, DOI 10.1097/01.ALC.0000042151.96124.52
  5. American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th
  6. Anton RF, 2004, J CLIN PSYCHOPHARM, V24, P421, DOI 10.1097/01.jcp.0000130555.63254.73
  7. Anton RF, 1999, AM J PSYCHIAT, V156, P1758
  8. Balldin J, 2003, ALCOHOL CLIN EXP RES, V27, P1142, DOI 10.1097/01.ALC.0000075548.83053.A9
  9. BORG V, 1983, ACTA PSYCHIAT SCAND, V68, P100, DOI 10.1111/j.1600-0447.1983.tb06987.x
  10. Caputo F, 2009, INT J ENV RES PUB HE, V6, P1917, DOI 10.3390/ijerph6061917
  11. Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P587, DOI 10.1093/alcalc/35.6.587
  12. CRABTREE BL, 1984, CLIN PHARMACY, V3, P273
  13. Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x
  14. de Bejczy A, 2015, ALCOHOL CLIN EXP RES, V39, P2189, DOI 10.1111/acer.12854
  15. Evans SM, 2007, ALCOHOL CLIN EXP RES, V31, P775, DOI 10.1111/j.1530-0277.2007.00360.x
  16. Falk DE, 2019, ALCOHOL CLIN EXP RES, V43, P158, DOI 10.1111/acer.13917
  17. Fogaca Marina N, 2011, BMC Clin Pharmacol, V11, P10, DOI 10.1186/1472-6904-11-10
  18. Fox HC, 2012, ALCOHOL CLIN EXP RES, V36, P351, DOI 10.1111/j.1530-0277.2011.01628.x
  19. Furieri FA, 2007, J CLIN PSYCHIAT, V68, P1691, DOI 10.4088/JCP.v68n1108
  20. GALLIMBERTI L, 1992, ALCOHOL CLIN EXP RES, V16, P673, DOI 10.1111/j.1530-0277.1992.tb00658.x
  21. Garbutt JC, 2016, JAMA PSYCHIAT, V73, P1056, DOI 10.1001/jamapsychiatry.2016.2157
  22. Garbutt JC, 2010, ALCOHOL CLIN EXP RES, V34, P1849, DOI 10.1111/j.1530-0277.2010.01273.x
  23. Gastpar M, 2002, J CLIN PSYCHOPHARM, V22, P592, DOI 10.1097/00004714-200212000-00009
  24. GOMEZ HJ, 1985, DRUGS, V30, P13, DOI 10.2165/00003495-198500301-00004
  25. GOTTLIEB LD, 1994, J SUBST ABUSE TREAT, V11, P253, DOI 10.1016/0740-5472(94)90083-3
  26. Guardia J, 2004, ALCOHOL CLIN EXP RES, V28, P736, DOI 10.1097/01.ALC.0000125352.06688.F7
  27. Guardia J, 2002, ALCOHOL CLIN EXP RES, V26, P1381, DOI 10.1097/01.ALC.0000030561.15921.A9
  28. Hammarberg A, 2009, BRAIN RES, V1305, pS2, DOI 10.1016/j.brainres.2009.09.093
  29. Higuchi S, 2015, J CLIN PSYCHIAT, V76, P181, DOI 10.4088/JCP.13m08940
  30. Huang MC, 2005, ADDICT BIOL, V10, P289, DOI 10.1080/13556210500223504
  31. Huang MC, 2014, J CLIN PSYCHOPHARM, V34, P149, DOI 10.1097/JCP.0000000000000052
  32. Hunter K, 2006, AM FAM PHYSICIAN, V74, P645
  33. Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790
  34. Ji YY, 2018, NEUROSCI LETT, V686, P133, DOI 10.1016/j.neulet.2018.09.006
  35. Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3
  36. Johnson BA, 2002, PSYCHOPHARMACOLOGY, V160, P408, DOI 10.1007/s00213-002-1002-9
  37. Johnson BA, 1996, PSYCHOPHARMACOLOGY, V128, P206, DOI 10.1007/s002130050126
  38. Kabel DI, 1996, ALCOHOL CLIN EXP RES, V20, P780, DOI 10.1111/j.1530-0277.1996.tb01686.x
  39. Kampman KM, 2007, J CLIN PSYCHOPHARM, V27, P344, DOI 10.1097/JCP.0b013e3180ca86e5
  40. Kenna GA, 2016, ADDICT BIOL, V21, P904, DOI 10.1111/adb.12275
  41. Khemiri L, 2019, ALCOHOL CLIN EXP RES, V43, P135, DOI 10.1111/acer.13910
  42. Kiefer F, 2005, J PSYCHIATR RES, V39, P545, DOI 10.1016/j.jpsychires.2004.11.005
  43. KIRCH W, 1982, EUR J DRUG METAB PH, V7, P81, DOI 10.1007/BF03188723
  44. Koethe D, 2007, ALCOHOL CLIN EXP RES, V31, P1188, DOI 10.1111/j.1530-0277.2007.00419.x
  45. Krupitsky E M, 2020, Zh Nevrol Psikhiatr Im S S Korsakova, V120, P33, DOI 10.17116/jnevro202012001133
  46. Krupitsky E M, 2015, Zh Nevrol Psikhiatr Im S S Korsakova, V115, P53, DOI 10.17116/jnevro20151156153-62
  47. LAWFORD BR, 1995, NAT MED, V1, P337, DOI 10.1038/nm0495-337
  48. Lê AD, 2011, PSYCHOPHARMACOLOGY, V218, P89, DOI 10.1007/s00213-011-2178-7
  49. Likhitsathian S, 2013, DRUG ALCOHOL DEPEN, V133, P440, DOI 10.1016/j.drugalcdep.2013.06.032
  50. Litten RZ, 2013, J ADDICT MED, V7, P277, DOI 10.1097/ADM.0b013e31829623f4
  51. Longo N, 2016, BBA-MOL CELL RES, V1863, P2422, DOI 10.1016/j.bbamcr.2016.01.023
  52. Malec E, 1996, ALCOHOL CLIN EXP RES, V20, P307, DOI 10.1111/j.1530-0277.1996.tb01644.x
  53. Manhapra A, 2019, J ADDICT MED, V13, P7, DOI 10.1097/ADM.0000000000000443
  54. Marra D, 2002, ALCOHOL CLIN EXP RES, V26, P1545, DOI 10.1097/01.ALC.0000034666.69418.47
  55. Martinotti G, 2022, CURR PHARM DESIGN, V28, P2241, DOI 10.2174/1381612828666220623092853
  56. Martinotti G, 2010, ALCOHOL ALCOHOLISM, V45, P449, DOI 10.1093/alcalc/agq039
  57. Mason BJ, 2014, JAMA INTERN MED, V174, P70, DOI 10.1001/jamainternmed.2013.11950
  58. MICHEL ME, 1985, METHOD FIND EXP CLIN, V7, P175
  59. Moher D., 2009, PLOS MED, V6, pe1000097, DOI 10.1371/journal.pmed.1000097
  60. Monterosso JR, 2001, AM J ADDICTION, V10, P258
  61. Morley KC, 2006, ADDICTION, V101, P1451, DOI 10.1111/j.1360-0443.2006.01555.x
  62. Morley KC, 2018, ADDICTION, V113, P2205, DOI 10.1111/add.14373
  63. Namkoong K, 2003, ALCOHOL ALCOHOLISM, V38, P135, DOI 10.1093/alcalc/agg038
  64. NARANJO CA, 1991, CLIN PHARMACOL THER, V50, P96, DOI 10.1038/clpt.1991.108
  65. O'Malley SS, 2018, ALCOHOL CLIN EXP RES, V42, P2011, DOI 10.1111/acer.13849
  66. Palma E, 2007, EPILEPSIA, V48, P1842, DOI 10.1111/j.1528-1167.2007.01131.x
  67. Pedersen CA, 2013, ALCOHOL CLIN EXP RES, V37, P484, DOI 10.1111/j.1530-0277.2012.01958.x
  68. Petrakis IL, 2018, ADDICTION, V113, P6, DOI 10.1111/add.13943
  69. Ponizovsky AM, 2015, J SUBST ABUSE TREAT, V52, P24, DOI 10.1016/j.jsat.2014.11.007
  70. Rasmussen DD, 2009, ALCOHOL CLIN EXP RES, V33, P264, DOI 10.1111/j.1530-0277.2008.00829.x
  71. Richter C, 2012, J CLIN PSYCHOPHARM, V32, P558, DOI 10.1097/JCP.0b013e31825e213e
  72. Rombouts SA, 2019, ALCOHOL ALCOHOLISM, V54, P272, DOI 10.1093/alcalc/agz026
  73. Rubio G, 2009, J CLIN PSYCHOPHARM, V29, P584, DOI 10.1097/JCP.0b013e3181bfdb79
  74. Shebek J, 2000, J ALTERN COMPLEM MED, V6, P45, DOI 10.1089/acm.2000.6.45
  75. Sills GJ, 2006, CURR OPIN PHARMACOL, V6, P108, DOI 10.1016/j.coph.2005.11.003
  76. Simpson TL, 2009, ALCOHOL CLIN EXP RES, V33, P255, DOI 10.1111/j.1530-0277.2008.00807.x
  77. Sinha R, 2022, ADDICT BIOL, V27, DOI 10.1111/adb.13116
  78. SITLANDMARKEN PA, 1990, J CLIN PSYCHIAT, V51, P68
  79. Strat Y, 2012, ALCOHOL CLIN EXP RES, V36, P1309, DOI 10.1111/j.1530-0277.2012.01891.x
  80. Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3
  81. The Joanna Briggs Institute, CRIT APPR TOOLS US J
  82. Trombley TA, 2020, ACS CHEM NEUROSCI, V11, P3850, DOI 10.1021/acschemneuro.9b00336
  83. Uchitel OD, 2010, CHANNELS, V4, P490, DOI 10.4161/chan.4.6.12864
  84. Umhau JC, 2011, NEUROPSYCHOPHARMACOL, V36, P1178, DOI 10.1038/npp.2010.253
  85. VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
  86. White HS, 2003, J CLIN PSYCHIAT, V64, P5
  87. who, 2022, TRACKING SARS COV 2
  88. Wiesbeck GA, 1999, ALCOHOL CLIN EXP RES, V23, P230
  89. Wong WM, 2008, PHARMACOPSYCHIATRY, V41, P72, DOI 10.1055/s-2007-1004595

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPer
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - ODS/03